A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1

被引:67
作者
Meyer, RD
Mohammadi, M
Rahimi, N
机构
[1] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA
[3] NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA
关键词
D O I
10.1074/jbc.M506454200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
VEGFR-1 is a kinase-defective receptor tyrosine kinase (RTK) and negatively modulates angiogenesis by acting as a decoy receptor. The decoy characteristic of VEGFR-1 is required for normal development and angiogenesis. To date, there is no molecular explanation for this unusual characteristic of VEGFR-1. Here we show that the molecular mechanisms underlying the decoy characteristic of VEGFR-1 is linked to the replacement of a highly conserved amino acid residue in the activation loop. This amino acid is highly conserved among all the type III RTKs and corresponds to aspartic acid, but in VEGFR-1 it is substituted to asparagine. Mutation of asparagine (Asn1050) within the activation loop to aspartic acid promoted enhanced ligand-dependent tyrosine autophosphorylation and kinase activation in vivo and in vitro. The mutant VEGFR-1 (Asp1050) promoted endothelial cell proliferation but not tubulogenesis. It also displayed an oncogenic phenotype as its expression in fibroblast cells elicited transformation and colony growth. Furthermore, mutation of the invariable aspartic acid to asparagine in VEGFR-2 lowered the autophosphorylation of activation loop tyrosines 1052 and 1057. We propose that the conserved aspartic acid in the activation loop favors the transphosphorylation of the activation loop tyrosines, and its absence renders RTK to a less potent enzyme by disfavoring transphosphorylation of activation loop tyrosines.
引用
收藏
页码:867 / 875
页数:9
相关论文
共 50 条
[31]   The phosphorylated 1169-tyrosine containing region of Flt-1 kinase (VEGFR-1) is a major binding site for PLC gamma [J].
Sawano, A ;
Takahashi, T ;
Yamaguchi, S ;
Shibuya, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 238 (02) :487-491
[32]   Neutralizing MoAb to VEGF receptors inhibit proliferation and migration of a subset of human leukemias through interaction with VEGFR-2(KDR) and VEGFR-1(FLT-1). [J].
Dias, S ;
Lane, WJ ;
Wu, Y ;
Choy, M ;
Peichev, M ;
Chadburn, A ;
Hyjeck, E ;
Roboz, G ;
Hicklin, D ;
Witte, L ;
Rafii, S .
BLOOD, 1999, 94 (10) :620A-620A
[33]   The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation [J].
Roberts, DM ;
Kearney, JB ;
Johnson, JH ;
Rosenberg, MP ;
Kumar, R ;
Bautch, VL .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (05) :1531-1535
[34]   The c-Cb1/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1) [J].
Kobayashi, S ;
Sawano, A ;
Nojima, Y ;
Shibuya, M ;
Maru, Y .
FASEB JOURNAL, 2004, 18 (03) :929-+
[35]   Expression of receptor tyrosine kinases VEGFR-1 (FLT-1), VEGFR-2 (KDR), EGFR-1, PDGFRα and c-Met in canine primary brain tumours [J].
Dickinson, P. J. ;
Roberts, B. N. ;
Higgins, R. J. ;
Leutenegger, C. M. ;
Bollen, A. W. ;
Kass, P. H. ;
LeCouteur, R. A. .
VETERINARY AND COMPARATIVE ONCOLOGY, 2006, 4 (03) :132-140
[36]   A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration [J].
Gille, H ;
Kowalski, J ;
Yu, LL ;
Chen, H ;
Pisabarro, MT ;
Davis-Smyth, T ;
Ferrara, N .
EMBO JOURNAL, 2000, 19 (15) :4064-4073
[38]   Human cancer cell lines resistant to EGFR inhibitors acquire an altered expression of VEGFR-1/Flt-1 and become sensitive to ZD6474 [J].
Bianco, Roberto ;
Daniele, Gennaro ;
Gelardi, Terese ;
Tuccillo, Concetta ;
Ryan, Anderson J. ;
Bianco, A. Raffaele ;
De Placido, Sabino ;
Ciardiello, Fortunato ;
Tortora, Giampaolo .
CANCER RESEARCH, 2006, 66 (08)
[39]   Absence of VEGFR-1/Flt-1 signaling pathway in mice results in insensitivity to discogenic low back pain in an established disc injury mouse model [J].
Qiu, Sujun ;
Shi, Changgui ;
Anbazhagan, Arivarasu Natarajan ;
Das, Vaskar ;
Arora, Vipin ;
Ranjan, Kc ;
Li, Xin ;
O-Sullivan, InSug ;
van Wijnen, Andre ;
Chintharlapalli, Sudhakar ;
Gott-Velis, Gina ;
Richard, Ripper ;
Mwale, Fackson ;
Shibuya, Masabumi ;
Min, Shaoxiong ;
Im, Hee-Jeong .
JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (06) :5305-5317
[40]   Muscle-mediated expression of soluble VEGFR-1/Flt-1 using AAV1 vector can suppress ovarian cancer growth in nude mice [J].
Takei, Y ;
Mizukami, H ;
Saga, Y ;
Kohno, S ;
Matsushita, T ;
Okada, T ;
Hanazono, Y ;
Kume, A ;
Suzuki, M ;
Ozawa, K .
MOLECULAR THERAPY, 2003, 7 (05) :S136-S136